GB0413005D0 - Ligand - Google Patents

Ligand

Info

Publication number
GB0413005D0
GB0413005D0 GBGB0413005.0A GB0413005A GB0413005D0 GB 0413005 D0 GB0413005 D0 GB 0413005D0 GB 0413005 A GB0413005 A GB 0413005A GB 0413005 D0 GB0413005 D0 GB 0413005D0
Authority
GB
United Kingdom
Prior art keywords
mammary cell
nrg3
variant
mammary
differentiation activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0413005.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BREAKTHROUGH BREAST CANCER
BASF Beauty Care Solutions France SAS
Institute of Cancer Research
Original Assignee
BREAKTHROUGH BREAST CANCER
Coletica SA
Institute of Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BREAKTHROUGH BREAST CANCER, Coletica SA, Institute of Cancer Research filed Critical BREAKTHROUGH BREAST CANCER
Priority to GBGB0413005.0A priority Critical patent/GB0413005D0/en
Publication of GB0413005D0 publication Critical patent/GB0413005D0/en
Priority to PCT/GB2005/002321 priority patent/WO2005120547A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals

Abstract

A method of promoting the differentiation of a mammary cell, the method comprising contacting the mammary cell with Neuregulin-3 (Nrg3) or a variant thereof which has mammary cell differentiation activity. A method of producing mammary tissue in vitro, the method comprising culturing cells in a 3D culture matrix and contacting the cells with Nrg3 or a variant thereof which has mammary cell differentiation activity. A method of preventing breast cancer in an individual, the method comprising administering to the individual Nrg3 or a variant thereof which has mammary cell differentiation activity.
GBGB0413005.0A 2004-06-11 2004-06-11 Ligand Ceased GB0413005D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0413005.0A GB0413005D0 (en) 2004-06-11 2004-06-11 Ligand
PCT/GB2005/002321 WO2005120547A1 (en) 2004-06-11 2005-06-13 Use of neuregulin-3 for inducing mammary cell differentiation and for the treatment of breast cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0413005.0A GB0413005D0 (en) 2004-06-11 2004-06-11 Ligand

Publications (1)

Publication Number Publication Date
GB0413005D0 true GB0413005D0 (en) 2004-07-14

Family

ID=32732286

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0413005.0A Ceased GB0413005D0 (en) 2004-06-11 2004-06-11 Ligand

Country Status (2)

Country Link
GB (1) GB0413005D0 (en)
WO (1) WO2005120547A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130296183A1 (en) * 2010-09-17 2013-11-07 President And Fellows Of Harvard College Functional genomics assay for characterizing pluripotent stem cell utility and safety
JP6697380B2 (en) 2013-06-10 2020-05-20 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Early developmental genomic assay to characterize the utility and safety of pluripotent stem cells
CN110946993A (en) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 Formula of neuregulin preparation
EP3143126A1 (en) 2014-05-16 2017-03-22 Koninklijke Nederlandse Akademie van Wetenschappen Improved culture method for organoids
GB201421094D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201421092D0 (en) * 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121415A (en) * 1997-07-09 2000-09-19 Genentech, Inc. ErbB4 receptor-specific neuregolin related ligands and uses therefor
WO2005040391A1 (en) * 2003-10-27 2005-05-06 Murdoch Childrens Research Institute Compositions and methods for differentiating stem cells

Also Published As

Publication number Publication date
WO2005120547A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
GB2434157A (en) Platelets from stem cells
BR0210599A (en) Use of carbon monoxide, method for maintaining an animal cell in vitro, article of manufacture as well as sterile cell medium
GB2554283A (en) Devices for simulating a function of a tissue and methods of use and manufacturing thereof
MX353245B (en) METHODS FOR REPROGRAMMING CELLS and USES THEREOF.
NZ594271A (en) Culture medium for epithelial stem cells and organoids comprising said stem cells
MX2015001871A (en) Natural killer cells and uses thereof.
WO2001036589A3 (en) Human ex vivo immune system
MX2009004238A (en) Methods and compositions for treatment of bone defects with placental cell populations.
MX2016008251A (en) Media for cell culture.
SG10201906494PA (en) Extracellular matrix compositions
WO2004113513A3 (en) Methods and compositions for modulating stem cell growth and differentiation
MX2008011521A (en) Facility module for production and storage of cell therapy product.
NZ608734A (en) Bone marrow derived cd271 precursor cells for cardiac repair
WO2003065999A3 (en) Proliferated cell lines and uses thereof
BR112013000822A2 (en) two-step method and method for producing an activated natural killer (nk) cell population, activated nk cell population and method for suppressing tumor cell proliferation
IL173488A0 (en) Scaffold-free self-organized 3d synthetic tissue
HK1156976A1 (en) Methods for producing hair microfollicles and de novo papillae and their use for in vitro tests and in vivo implantations
WO2008055224A3 (en) Lithium stimulation of cord blood stem cell proliferation and growth factor production
WO2007146267A3 (en) Disease model incorporation into an artificial immune system (ais)
HK1099324A1 (en) Open-pored polyurethane foam without skin formation, formulation for the production thereof and use thereof as a carrier material for cell and tissue cultures or medicaments
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
GB0413005D0 (en) Ligand
AU2001270656A1 (en) Three-dimensional structure biocompatible polymer with communicating cells, preparation method and use in medicine and surgery
HK1076294A1 (en) Procedure for the large-scale t-lymphocytes culture in a homogeneous system
WO2008063759A3 (en) A method of increasing retention, survival and proliferation of transplanted cells in vivo

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)